We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Integer Holdings (ITGR) in Q3 Earnings?
Read MoreHide Full Article
Integer Holdings Corporation (ITGR - Free Report) is expected to release third-quarter 2018 results on Nov 1. The company expects steady growth in the Cardio & Vascular product line.
Q2 Results at a Glance
Integer posted adjusted earnings of $1.06 per share in the second quarter of 2018, up 43% year over year. Further, earnings beat the Zacks Consensus Estimate of 90 cents.
Revenues rose 12% year over year to $314 million on a reported basis and missed the Zacks Consensus Estimate of $382 million.
On an average, the company delivered a positive earnings surprise of 24% in the trailing four quarters.
Integer Holdings Corporation Price and EPS Surprise
For the third quarter, the Zacks Consensus Estimate for revenues is pegged at $292 million, indicating a year-over-year decline of 19.6%. The consensus estimate for earnings is pegged at 92 cents, reflecting a year-over-year rise of 12.2%.
Let’s delve deeper.
Factors to Consider
Cardio & Vascular product line
In the third quarter, the Cardio & Vascular product line is expected to boost the top line. The upside will be driven by strong revenues in the peripheral vascular, neurovascular and electrophysiology markets.
Catheter revenues in electrophysiology as well as catheter & guidewire revenues in the peripheral vascular and neurovascular markets are expected to be strong in the quarter to be reported.
In the last reported quarter, Cardio & Vascular product line platform witnessed 13% year-over-year sales growth.Integer’s long-term objective in Cardio & Vascular is to continue to deliver double-digit growth on a sustainable basis in the quarter to be reported.
Cardiac & Neuromodulation
Strong prospects in the neuromodulation market are key drivers for long-term growth forCardiac & Neuromodulation product line. Management at Integer announced that the company is focused on accelerating neuromodulation sales through expanding customer base.
In the last reported quarter, revenues in the segment totaled $115.9 million, up 9.2% from the prior-year quarter’s tally. On a comparable organic constant-currency basis as well, revenues increased 9.2%.
We expect strength in Cardiac & Neuromodulation product line in the quarter to be reported as well.
For investors’ notice, Integer expects adjusted earnings per share (EPS) in the range of $3.35-$3.65 for the 2018. This reflects growth of 9-19% year over year. The Zacks Consensus Estimate for 2018 adjusted earnings is currently pegged at $3.57, within the range. Adjusted sales are anticipated between $1.18 billion and $1.20 billion, indicating growth of 4-6%. Meanwhile, the Zacks Consensus Estimate is pegged at $1.24 billion, which is considerably higher than the projected range.
Earnings Whispers
Per our proven quantitative model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. This is not the case here as you will see below.
Earnings ESP:Integer has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:Integer carries a Zacks Rank #3.
Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is witnessing negative estimate revision.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in their upcoming quarterly results.
Haemonetics Corporation (HAE - Free Report) has an Earnings ESP of +5.56% and a Zacks Rank #1.
Amgen Inc (AMGN - Free Report) has an Earnings ESP of +3.54% and a Zacks Rank #2.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
What's in Store for Integer Holdings (ITGR) in Q3 Earnings?
Integer Holdings Corporation (ITGR - Free Report) is expected to release third-quarter 2018 results on Nov 1. The company expects steady growth in the Cardio & Vascular product line.
Q2 Results at a Glance
Integer posted adjusted earnings of $1.06 per share in the second quarter of 2018, up 43% year over year. Further, earnings beat the Zacks Consensus Estimate of 90 cents.
Revenues rose 12% year over year to $314 million on a reported basis and missed the Zacks Consensus Estimate of $382 million.
On an average, the company delivered a positive earnings surprise of 24% in the trailing four quarters.
Integer Holdings Corporation Price and EPS Surprise
Integer Holdings Corporation Price and EPS Surprise | Integer Holdings Corporation Quote
Which Way are Estimates Treading?
For the third quarter, the Zacks Consensus Estimate for revenues is pegged at $292 million, indicating a year-over-year decline of 19.6%. The consensus estimate for earnings is pegged at 92 cents, reflecting a year-over-year rise of 12.2%.
Let’s delve deeper.
Factors to Consider
Cardio & Vascular product line
In the third quarter, the Cardio & Vascular product line is expected to boost the top line. The upside will be driven by strong revenues in the peripheral vascular, neurovascular and electrophysiology markets.
Catheter revenues in electrophysiology as well as catheter & guidewire revenues in the peripheral vascular and neurovascular markets are expected to be strong in the quarter to be reported.
In the last reported quarter, Cardio & Vascular product line platform witnessed 13% year-over-year sales growth.Integer’s long-term objective in Cardio & Vascular is to continue to deliver double-digit growth on a sustainable basis in the quarter to be reported.
Cardiac & Neuromodulation
Strong prospects in the neuromodulation market are key drivers for long-term growth forCardiac & Neuromodulation product line. Management at Integer announced that the company is focused on accelerating neuromodulation sales through expanding customer base.
In the last reported quarter, revenues in the segment totaled $115.9 million, up 9.2% from the prior-year quarter’s tally. On a comparable organic constant-currency basis as well, revenues increased 9.2%.
We expect strength in Cardiac & Neuromodulation product line in the quarter to be reported as well.
For investors’ notice, Integer expects adjusted earnings per share (EPS) in the range of $3.35-$3.65 for the 2018. This reflects growth of 9-19% year over year. The Zacks Consensus Estimate for 2018 adjusted earnings is currently pegged at $3.57, within the range. Adjusted sales are anticipated between $1.18 billion and $1.20 billion, indicating growth of 4-6%. Meanwhile, the Zacks Consensus Estimate is pegged at $1.24 billion, which is considerably higher than the projected range.
Earnings Whispers
Per our proven quantitative model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. This is not the case here as you will see below.
Earnings ESP:Integer has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:Integer carries a Zacks Rank #3.
Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is witnessing negative estimate revision.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat in their upcoming quarterly results.
Haemonetics Corporation (HAE - Free Report) has an Earnings ESP of +5.56% and a Zacks Rank #1.
Amgen Inc (AMGN - Free Report) has an Earnings ESP of +3.54% and a Zacks Rank #2.
Anthem, Inc has an Earnings ESP of +1.69% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>